CN Patent

CN102149711A — 有机化合物

Assigned to Novartis AG · Expires 2011-08-10 · 15y expired

What this patent protects

本发明涉及式(I)化合物或其盐，其中取代基如说明书所定义，还涉及组合物和所述化合物在治疗通过抑制磷脂酰肌醇3-激酶来改善的疾病中的用途。

USPTO Abstract

本发明涉及式(I)化合物或其盐，其中取代基如说明书所定义，还涉及组合物和所述化合物在治疗通过抑制磷脂酰肌醇3-激酶来改善的疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN102149711A
Jurisdiction
CN
Classification
—
Expires
2011-08-10
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.